Greg is a Managing Director in Healthcare Investment Banking at the Royal Bank of Canada. Prior to that he was at Deutsche Bank for 5 years and before that spent 25 years at Merck & Co. as a scientist. Following several years in Basic Research, Greg was VP & Head of Search & Evaluation at Merck for 13 years and managed 85 employees worldwide including 31 PhD/MD scientists. While leading the group, the team successfully completed deals on 30 clinical/marketed compounds, 16 preclinical compounds, 48 discovery stage compounds, 49 research technologies/formulations, and seven company acquisitions (Schering Plough, Sirna, Glycofi, Abmaxis, Aton, SmartCells, and Inspire). Through the group’s efforts, sixty-three percent of Merck revenue was at that time derived from licensed compounds/biologicals/vaccines or entities that could not be marketed if not for a very significant license. With Corporate Finance, Greg launched a $285MM venture fund, the Merck Research Venture Fund for the purpose of investing in early-stage biotech companies. While at RBC as a Managing Director and, prior to that, at Deutsche Bank, Greg advised on Merck’s acquisition of Cubist ($9.5bn), Lilly’s acquisition of Loxo Oncology ($8bn; sole advisor to Lilly), Alexion’s acquisition of Achillion ($930mm), and Alexion’s acquisition of Portola ($1.4bn; sole advisor to Alexion). He has advised on financings (IPOs, Follow-Ons, Debt, Lev Fin) for several large pharmas and biotechs. Greg has been an invited speaker, keynote speaker, panelist, or plenary/keynote panelist at 87 conferences worldwide and he has been an author on 48 peer reviewed scientific publications.